The analysis further found that while mean annual patient out-of-pocket payments decreased, mean total annual payments per user increased in nominal dollars, raising affordability concerns, particularly if treatment continues over a lifetime
Retatrutides Phase 2 data demonstrating 24.2% mean body weight reduction approaches bariatric surgery outcomes without surgical risk
Ongoing registry and pharmacovigilance data therefore remain important
They can: For many women, this can make it easier to create a calorie deficit and lose weight
This could promote abnormal blood vessel growth
Self-directed peptide use can also be risky for patients taking multiple medications, patients with liver or kidney concerns, people with bleeding disorders, and anyone who has experienced unusual reactions to injectable products